Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Long-Term Debt Repayments (2018 - 2020)

KalVista Pharmaceuticals' Long-Term Debt Repayments history spans 3 years, with the latest figure at $1000.0 for Q2 2020.

  • For Q2 2020, Long-Term Debt Repayments fell 98.15% year-over-year to $1000.0; the TTM value through Apr 2020 reached $54000.0, down 74.16%, while the annual FY2020 figure was $54000.0, 74.16% down from the prior year.
  • Long-Term Debt Repayments for Q2 2020 was $1000.0 at KalVista Pharmaceuticals, up from -$1000.0 in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $54000.0 in Q2 2019 and bottomed at -$1000.0 in Q1 2020.
  • The 3-year median for Long-Term Debt Repayments is $52000.0 (2018), against an average of $40555.6.
  • The largest annual shift saw Long-Term Debt Repayments increased 8.0% in 2019 before it plummeted 101.96% in 2020.
  • A 3-year view of Long-Term Debt Repayments shows it stood at $52000.0 in 2018, then grew by 3.85% to $54000.0 in 2019, then crashed by 98.15% to $1000.0 in 2020.
  • Per Business Quant, the three most recent readings for KALV's Long-Term Debt Repayments are $1000.0 (Q2 2020), -$1000.0 (Q1 2020), and $54000.0 (Q3 2019).